Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors

Hira Cheema, Asis Shrestha, Syed Naqvi, Sanjay Muttineni, Sasya Dronavalli, Jawad Alrawabdeh, Marah Alzubi, Sharmilan Thanendrarajan, Maurizio Zangari, John D Shaughnessy, Jr, Fenghuang Zhan, Carolina Schinke, Frits van Rhee, Samer Al Hadidi

Blood (2025) 146 (Supplement 1): 4599.

https://doi.org/10.1182/blood-2025-4599

Published: 2025

Journal Articles

Real-world outcomes of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) following CAR T-cell therapy: A multicenter retrospective study from the trinetx global network

Syed Naqvi, Ejaz Shah, Firas Jafri, Syed Muhammad Ali Najafi, Manpreet Saini, Syed Abutalib, Maurizio Zangari, Frits van Rhee, Ankur Varma

Blood (2025) 146 (Supplement 1): 7247.

https://doi.org/10.1182/blood-2025-7247

Published: 2025

Journal Articles

Anticoagulation dilemma in a patient with nephrotic syndrome and bleeding of unknown origin: A case-based approach to risk-benefit decision-making

Amanda Lussier, Abdul Khan, Jatin Thukral, Sooraj Srirangadhamu Gopu, Ahmed Nadeem, Syed Naqvi

Blood (2025) 146 (Supplement 1): 6645.

https://doi.org/10.1182/blood-2025-6645

Published: 2025

Journal Articles

The disguise of dyscrasia: Hereditary von Willebrand disease unmasked by MGUS-associated acquired VWD

Amanda Lussier, Sooraj Srirangadhamu Gopu, Jatin Thukral, Ahmed Nadeem, Syed Naqvi

Blood (2025) 146 (Supplement 1): 6644.

https://doi.org/10.1182/blood-2025-6644

Published: 2025

Journal Articles

Real-world outcomes and toxicities of elranatamab (ELRA) in relapsed/refractory multiple myeloma: A retrospective analysis using the trinetx global health research network.

Syed Naqvi, Ejaz Shah, Firas Jafri, Manpreet Saini, Syed Abutalib, Maurizio Zangari, Carolina Schinke, Sharmilan Thanendrarajan, Samer Al Hadidi, Frits van Rhee

Blood (2025) 146 (Supplement 1): 7597.

https://doi.org/10.1182/blood-2025-7597

Published: 2025

Journal Articles

Real-world outcomes and toxicities of talquetamab (Tal) in Relapsed/Refractory multiple myeloma (RRMM): A retrospective analysis using the trinetx global health research network.

Syed Naqvi, Manpreet Saini, Ejaz Shah, Firas Jafri, Syed Abutalib, Samer Al Hadidi, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Frits van Rhee

Blood (2025) 146 (Supplement 1): 7595.

https://doi.org/10.1182/blood-2025-7595

Published: 2025

Journal Articles

Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)

Sharmilan Thanendrarajan, Phil Farmer, Clyde Bailey, Carolina Schinke, Samer Al Hadidi, Maurizio Zangari, Stephanie Rogers, Anne Williams, Fenghuang Zhan, John D Shaughnessy, Jr, Tanvi H. Patel, Anup Kumar Trikannad, Asis Shrestha, Syed Naqvi, Hira Imad Cheema, Trilok Shrivastava, Manozna Karri, Ramya Bachu, Frits van Rhee

Blood (2024) 144 (Supplement 1): 4713.

https://doi.org/10.1182/blood-2024-206152

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors

Real-world outcomes of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) following CAR T-cell therapy: A multicenter retrospective study from the trinetx global network

Anticoagulation dilemma in a patient with nephrotic syndrome and bleeding of unknown origin: A case-based approach to risk-benefit decision-making

The disguise of dyscrasia: Hereditary von Willebrand disease unmasked by MGUS-associated acquired VWD

Real-world outcomes and toxicities of elranatamab (ELRA) in relapsed/refractory multiple myeloma: A retrospective analysis using the trinetx global health research network.

Real-world outcomes and toxicities of talquetamab (Tal) in Relapsed/Refractory multiple myeloma (RRMM): A retrospective analysis using the trinetx global health research network.

Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)

Email alerts

ASH Publications

American Society of Hematology

Update search

Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors

Real-world outcomes of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) following CAR T-cell therapy: A multicenter retrospective study from the trinetx global network

Anticoagulation dilemma in a patient with nephrotic syndrome and bleeding of unknown origin: A case-based approach to risk-benefit decision-making

The disguise of dyscrasia: Hereditary von Willebrand disease unmasked by MGUS-associated acquired VWD

Real-world outcomes and toxicities of elranatamab (ELRA) in relapsed/refractory multiple myeloma: A retrospective analysis using the trinetx global health research network.

Real-world outcomes and toxicities of talquetamab (Tal) in Relapsed/Refractory multiple myeloma (RRMM): A retrospective analysis using the trinetx global health research network.

Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only